Funding from NIH, U-M, and NephCure International to Support Research of Major Cause of Rare Kidney Diseases
The National Center for Advancing Translational Sciences (NCATS) and the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) recently awarded a third five-year cycle of funding to support the Nephrotic Syndrome Study Network (NEPTUNE), a member of the Rare Diseases Clinical Research Network (RDCRN).
The Nephrotic Syndrome Research Network is revolutionizing the field of glomerular kidney disease research
Now in its ninth year, the benefits of laying the groundwork for the Nephrotic Syndrome Research Network (NEPTUNE) are beginning to come into fruition. As NephCure CEO Josh Tarnoff notes, “It’s hard to overstate NEPTUNE’s impact on our understanding of FSGS and related syndromes. For example, one of the data sets presented by NEPTUNE at ASN Kidney Week 2016 provided the much-needed evidence correlating proteinuria levels to survival. This no doubt assisted the FDA to evolve their guidelines to accept proteinuria…
Patients with Chronic Kidney Disease (CKD) may benefit from a new collaboration between U-M and AstraZeneca, who have partnered to develop a new therapeutic strategy for treatment. The partners will jointly conduct chemistry and drug discovery research with the aim of...
As the world gets smaller, Michigan Medicine’s place in it gets bigger. That’s thanks to partnerships like the one which recently took nearly 80 faculty abroad to meet with research collaborators in China.
We recently collaborated with Emily Somers, Ph.D., Sc.M., an associate professor of internal medicine (rheumatology), environmental health sciences and obstetrics and gynecology at U-M and a member of the U-M Institute for Healthcare Policy and Innovation, to help...
Pre-competitive consortium will work to identify new treatment targets for renal disease
Every day, our kidneys filter more than 30 gallons of blood to allow excretion of molecules that can harm us if they build up as waste. But, for more than 20 million Americans and a growing number of people around the world, this important function is compromised by...
Fast-tracking precision medicine: Science guides re-aiming of drug to target diabetic kidney disease
U-M scientists’ lab work revealed cell-signaling target; partnership with drug company led to Phase II clinical trial results presented this week
Results from a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Baricitinib in Diabetic Kidney Disease
Poster session from ADA Scientific Sessions.
Boehringer Ingelheim and researchers at The University of Michigan collaborate to study mechanisms of diabetic nephropathy in Pima Indians
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.